Turkmenistan Medical Device Market Access: No EAEU and No EU Reliance Pathway

1. Key takeaways

Turkmenistan is neither a member of the Eurasian Economic Union (EAEU) nor a member of the European Union. These are two independent factual judgments.

From this follow the most fundamental conclusions about market access in this country:

• An EAEU registration certificate does not constitute a basis for access to Turkmenistan;
• CE marking does not constitute a basis for simplified review or exemption from review;
• No reliance or mutual recognition channel exists;
• Every device must pass through the national registration pathway of Turkmenistan itself. For planning purposes this is the single most consequential fact about the market: it removes every shortcut that exists in neighboring jurisdictions and fixes the workload at the full national procedure.

2. Legal basis

3. Expert insights

Insight 1: This is the largest institutional divergence between Turkmenistan and the neighboring markets.

Kazakhstan, Russia, Belarus, Kyrgyzstan and Armenia all operate under the unified EAEU rules for the circulation of medical devices. Turkmenistan, although part of the same region geographically and linguistically, stands institutionally completely outside that system. Regional experience with EAEU dossiers therefore transfers poorly, and planning assumptions imported from neighboring countries must be rebuilt from the national legal base. It also means that no regional appointment, such as a single representative covering several countries, can substitute for the local representation required by the national framework.

Insight 2: The market plan of treating Central Asia as five countries at once does not hold for device registration.

Among the five Central Asian states, Kazakhstan and Kyrgyzstan use the EAEU channel, while Uzbekistan, Tajikistan and Turkmenistan each maintain their own national pathway. Treating an EAEU certificate as a universal access credential for Central Asia is a misjudgment that causes real losses, because it delays the start of the separate national procedures that are actually required. Portfolio planning should therefore carry separate timelines, separate budgets and separate local partners for each of the three non-EAEU markets.

Insight 3: In this system, foreign certificates serve as corroboration, not as a basis.

Article 16 of this series explained that a free sale certificate and a certificate of registration in the country of origin are required. These documents serve to show that the product is lawfully marketed elsewhere (corroborating its safety), not to replace the local review. The assessment conclusion is reached by the Turkmen competent authority on its own responsibility. In practice, the review still examines the safety, quality and effectiveness evidence in full, and foreign approval letters shorten nothing in the procedure itself.

Insight 4: The same judgment determines that documentation cannot simply be copied over.

The EAEU registration dossier format and the CE technical documentation structure (such as Annexes II and III of the EU Medical Device Regulation) are not the national format of Turkmenistan. Article 12 of this series explained that other formats such as CTD require the prior consent of the competent authority. Reusing a foreign dossier layout is something that must first be approved; it is not a default option. The safest course is to prepare the national format from the outset and treat any other format as an exception requiring written consent.

Insight 5: The expectation, common among manufacturers, that a CE certificate opens every door must be adjusted here.

In this market the value of a CE certificate is limited to demonstrating that the product has undergone third-party conformity assessment, as one element of the technical documentation. It cannot shorten the review period, reduce the documentation, or exempt the product from samples and laboratory analysis. Budgeting and scheduling must assume a full national review regardless of the certificates held. Commercial teams should be briefed accordingly, so that sales forecasts do not assume the shorter cycles associated with reliance pathways elsewhere.

4. Practical recommendations

1. Plan on the basis of a pathway without reliance, treating neither EAEU nor CE documents as a basis for simplification.
2. Plan the Central Asian markets country by country, without assuming that EAEU coverage extends across the region.
3. Position foreign certificates as corroborating material within the documentation system.
4. Do not copy EAEU or CE dossier formats; prepare the dossier in the national format of Turkmenistan.
5. If formats such as CTD are to be used, obtain the consent of the competent authority in advance.

5. Verification checklist

• □ The plan has been prepared on the basis of a pathway without reliance.
• □ Registration pathways for the Central Asian countries have been planned separately.
• □ Foreign certificates have been positioned as corroborating material.
• □ The dossier has been prepared in the national format of Turkmenistan.
• □ The use of formats such as CTD has been consented to in advance.

Regulatory information verified as of October 30, 2026. The content cited in this document was checked against the Law on the Supply of Medicines No. 319-V (January 12, 2016, national registration as the precondition for marketing) and against Decision No. 78 of the Board of the Eurasian Economic Commission (November 3, 2016, amended in 2025) and Decision No. 34 (adopted May 22, 2025, effective June 21, 2025). The latter two instruments apply only to EAEU member states; Turkmenistan is not a member, so they are not applicable and are cited here for comparison purposes only.

• Local resources in Turkmenistan: GRZAN can coordinate licensed local import entities and authorized representative resources, covering state registration submission, the consular legalization chain for documents, sample delivery, coordination with mandatory TDS certification and customs clearance support.
• Service capabilities: classification determination, registration pathway selection, dossier preparation in the national format, consular legalization and notarization, test and stability documentation, GMP and ISO 13485 evidence organization, variations and re-registration, vigilance and post-market maintenance.
• Contact: info@grzanglobal.com. GRZAN provides registration support in this country for manufacturers, importers and authorized representatives.